Leadership Overview
MiMedx Group has 4 executives leading key functions including corporate strategy, financial operations, clinical development, and administrative governance.
Focused on advancing regenerative medicine through proprietary placental tissue technologies, MiMedx Group delivers innovative allografts to improve patient outcomes across wound care, surgical, and orthopedic sectors globally.
Focused on advancing regenerative medicine through proprietary placental tissue technologies, MiMedx Group delivers innovative allografts to improve patient outcomes across wound care, surgical, and orthopedic sectors globally.
Leadership Roles at MiMedx Group
Joseph Capper - Chief Executive Officer
Joseph Capper, the Chief Executive Officer at MiMedx Group, directs the overarching corporate strategy and long-term vision for the organization. Overseeing the development of regenerative biologics, Capper ensures the company maintains a competitive edge in the biopharmaceutical market. This leadership role involves aligning internal research initiatives with external market demands for advanced placental tissue allografts. By fostering collaboration across departments, Capper drives operational excellence and sustainable growth. The Chief Executive Officer manages high-level relationships with stakeholders and the Board to secure the financial health of the enterprise. Through the implementation of the proprietary PURION Process, Capper expands the reach of AmnioFix and EpiFix technologies into diverse healthcare sectors. Joseph Capper maintains a focus on scaling operations to meet the increasing demand for musculoskeletal repair solutions, ensuring the company remains a leader in the regenerative medicine industry while delivering consistent value to shareholders and patients alike.

Doug Rice - Chief Financial Officer
Doug Rice, the Chief Financial Officer at MiMedx Group, manages the fiscal health and capital allocation strategies for the organization. Overseeing financial planning, reporting, and risk management, Rice ensures the company maintains the necessary liquidity to support ongoing research and development of placental tissue allografts. This leadership role involves optimizing the cost structure of the proprietary PURION Process to maximize margins across the product portfolio. By analyzing market trends and operational performance, Rice provides the data-driven insights required for strategic decision-making at the executive level. The Chief Financial Officer coordinates with the sales force and distribution partners to monitor revenue streams across North American and international markets. Doug Rice secures the financial stability required to advance the CollaFix and AmnioCord platforms, ensuring that capital investments align with the long-term growth objectives of the business. Through rigorous financial oversight, Rice supports the expansion of the company into new clinical applications.
David Mason - Head Chief Marketing Officer, Clinical Development
David Mason, the Head Chief Marketing Officer, Clinical Development at MiMedx Group, architects the commercialization strategy and clinical evidence programs for the company. Overseeing the translation of scientific data into market-ready messaging, Mason ensures that the benefits of AmnioFix and EpiFix are clearly communicated to healthcare providers. This leadership role involves managing the clinical development pipeline to validate the efficacy of allografts in wound care, burns, and sports medicine. By bridging the gap between clinical research and commercial adoption, Mason drives the market penetration of advanced tissue technologies. The Head Chief Marketing Officer, Clinical Development coordinates with the direct sales force to equip representatives with the technical knowledge required for complex surgical environments. David Mason monitors the competitive landscape to refine product positioning and capture additional market share. Through the integration of clinical insights into marketing campaigns, Mason accelerates the adoption of regenerative solutions, ultimately enhancing the standard of care for patients requiring musculoskeletal repair.
William Hulse - General Counsel & Chief Administrative Officer
William Hulse, the General Counsel & Chief Administrative Officer at MiMedx Group, governs the legal framework and administrative infrastructure of the organization. Overseeing regulatory compliance and intellectual property protection, Hulse ensures the proprietary PURION Process and associated technologies remain secure within the competitive biopharmaceutical landscape. This leadership role involves managing corporate governance, risk mitigation, and legal affairs to support the operational integrity of the company. By streamlining administrative processes, Hulse improves organizational efficiency and ensures alignment with industry standards across all departments. The General Counsel & Chief Administrative Officer collaborates with the executive team to navigate complex legal challenges associated with international distribution and product licensing. William Hulse provides the foundational support necessary for the company to scale its operations in the United States and abroad. Through the management of legal and administrative functions, Hulse protects the assets of the business while facilitating the seamless execution of corporate initiatives and strategic partnerships.
Explore Leadership Teams in Manufacturing
ResMed is a global healthcare technology company that develops innovative medical devices, digital health solutions, and cloud-connected software to improve the diagnosis, treatment, and management of sleep disorders, respiratory conditions, and care delivered outside traditional hospital settings. The company partners with healthcare providers, patients, and caregivers to enhance health outcomes, streamline care delivery, and improve quality of life through connected technologies, data-driven insights, and ongoing innovation in medical care.
Company Leadership
NP
Omnicell, Inc. is a Fort Worth, Texas-based global healthcare technology company founded in 1992 and publicly traded on Nasdaq (OMCL). The company specializes in medication management solutions and adherence tools for healthcare systems and pharmacies, offering automated dispensing systems, robotic pharmacy automation, analytics software, supply management technologies, and patient engagement solutions under its EnlivenHealth brand. Omnicell's products serve inpatient, outpatient, and retail pharmacy settings across the United States, Canada, the United Kingdom, France, Germany, and Australia, helping healthcare providers reduce medication errors, improve patient safety, and increase operational efficiency.
Company Leadership



Hologic is a global medical technology leader focused on improving womens health and wellbeing through early detection, diagnosis, and treatment solutions. The company develops and supplies advanced diagnostic products, imaging systems, and surgical tools that support clinical care across breast health, gynecological care and infectious disease testing. With a strong innovation culture and worldwide presence, Hologic partners with healthcare professionals to raise standards of care and help patients live healthier lives.
Company Leadership
AL


As per the "buy and build" strategy, the next acquisition was Legacy Medical (July 2018), followed by Haemotec (Nov 2019) and LTE Medical Supplies (Feb 2019). In April 2019, the company started an Ophthalmology business (EyeCare) and have expanded the company's product range and agencies in the existing verticals. The second half of 2019 saw further acquisitions with Paragmed in November and Jumla Medical Supplies and Stratmed joining the group in December. The company is a scaled and diversified group of specialised medical service providers committed to bringing new, first-rate technologies to a wide spectrum of medical practitioners. The company provides the latest devices, software, processes and procedures that facilitate high care and quality treatment for all patients. The company's clients and partners continually receive extensive training and comprehensive technical support as the company strives towards better products, better services and more personalised customer experiences. Depiction of Vertice MedTech
Company Leadership HP
GS
BM
EM